Date: 2022-02-23

Type of information: Construction of new premises

Compound: sterile fill and finish production capabilities in Recipharm's site in Monts, France

Company: Recipharm (Sweden)

Therapeutic area: Technology - Services

Type agreement: construction of new premises

Action mechanism:



Recipharm has announced that the company is investing to expand its sterile fill and finish production capabilities at its site in Monts, France. The manufacturing facility which specialises in the aseptic filling of pharmaceutical products, including biologics into vials and cartridges, currently has three lines for vials. The investment will expand Recipharm’s manufacturing footprint by adding a state-of-the-art, high-speed filling line that is able to fill 400 vials a minute, with the capacity for more than 100 million vials per year. This project has been partly financed by the French government within the framework of the Future Investment Programme (Programme d’investissements d’avenir).
The new line, which has automated visual inspection and container closure integrity testing features, will have a >5 fold increased filling speed allowing temperature sensitive biologics to be filled. Recipharm will also provide secondary packaging and labelling from the facility. The new line will be fully commissioned in Q2 2022 and is expected to be operational for commercial production in Q3 2022. Recipharm is also in the process of implementing new cleanroom facilities and labs for microbiology and in-process controls. The site in Monts is one of Recipharm’s principal sterile manufacturing facilities and has seen significant growth in recent years in the fill & finish of an mRNA vaccine. It will continue to deliver batches of COVID-19 vaccines to support vaccination programmes around the world. The investment is part of a wider growth plan which also sees the CDMO investing in new fill and finish facilities in India (1 and 2) and Morocco. The additional sites will complement Recipharm’s existing sites in France, Germany and Italy and will be focused on securing approvals from regulators in Europe and the U.S.  

Financial terms:

Latest news:

Is general: Yes